Altimmune, Inc. Stock News

Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidat

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commer

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing intern

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing intern

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during

Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is part

Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is dev

Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results

Shares of Altimmune Inc. were down 4.1% in trading on Thursday, the day after the clinical-stage company said it had received regulatory approval to begin studying its COVID-19 vaccine candidate in a

The company's COVID-19 program is moving ahead.

Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free

No kidding around ... here's how they truly can.